Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  PAREXEL International Corporation    PRXL

News SummaryMost relevantAll newsSector newsTweets

PAREXEL International Corporation : Perceptive Informatics® Global Survey Results Show Significant Adoption of Web-based RTSM Systems by Clinical Sites

share with twitter share with LinkedIn share with facebook
share via e-mail
03/14/2012 | 11:05am CET

BOSTON, March 14, 2012 /PRNewswire/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of its Randomization and Trial Supply Management (RTSM) Survey, which tracked the evolving use of RTSM technologies, also known as Interactive Voice and Web Response Systems (IVRS/IWRS), by investigative sites worldwide. The survey polled professionals at nearly 300 investigative sites across the Americas, Europe and Asia. Results revealed a significant level of adoption of web- over voice-based versions of these technologies.

Used to randomize patients for study enrollment and manage various aspects of trial management, web-based RTSM systems provide investigative sites with the ability to collect and report on study data in real-time. According to the Perceptive Informatics analysis, this increased efficiency has provided a competitive advantage to sites in the selection process of clinical trial sponsors, who are seeking faster patient enrollment and a track record of high performance for global studies.

The Perceptive Informatics analysis showed that 65% of respondents worldwide use web-based RTSM systems to support clinical study execution. The Asia/Pacific region led all other geographies with the highest use of web- over voice-based systems, followed by Europe. In terms of the type of environment, 68% of hospital-based clinics and 61% of physician-based sites prefer web-based systems. According to the Perceptive Informatics survey, the top three reasons cited by respondents for their preference of web-based RTSM technologies include ease of use, speed, and convenience. Main uses of web-based RTSM technologies among investigative sites include drug accountability, identifying missing or damaged medication, and making dose adjustments.

"Sponsors are seeking to drive continuous process improvement in their clinical trial programs, and we have developed our eClinical solutions to support this goal. The results of this study are consistent with our commitment to advance flexible, web-based RTSM technologies," said Nick Richards, Vice President, Product Development, Perceptive Informatics. "We are focused on empowering investigative sites to improve their performance. By harnessing the power of web-based RTSM technology, sites can simplify their workflows and conduct study management activities more efficiently."

The ClinPhone(®) RTSM service from Perceptive Informatics offers validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities, and real-time supply reporting. The solutions provide sophisticated reporting to monitor trial management performance, trending and forecasting information, and in-depth data analysis. Clinical trials worldwide can be supported in multiple languages through the solutions, which provide secure access, a detailed audit trail, transaction logging, and compliance with FDA 21 CFR Part 11.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, ClinPhone is a registered trademark of ClinPhone Limited, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird, Senior Director of Public Relations Kim Leadley/Gene Carozza
    PAREXEL International                               PAN Communications
    Tel: +781-434-4409                                  Tel: + 617-502-4300
    Email: [email protected]                   Email: [email protected]

SOURCE PAREXEL International Corporation

© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
2017 PAREXEL INTERNATIONAL : Launches Perceptive® Cloud for the Life Sciences Industr..
2017 PAREXEL INTERNATIONAL : Expands Global Regulatory Services with Addition of Seni..
2017 PAREXEL INTERNATIONAL : Pamplona Capital Management Completes Acquisition of PAR..
2017 PAREXEL INTERNATIONAL CORPORATION (N : PRXL) Files An 8-K Entry into a Material ..
2017 PAREXEL INTERNATIONAL : Pamplona Capital Management Completes Acquisition of PAR..
2017 PAREXEL INTERNATIONAL CORP : Entry into a Material Definitive Agreement, Termina..
2017 PAREXEL INTERNATIONAL : Pamplona Capital Management Completes Acquisition of PAR..
2017 PAREXEL INTERNATIONAL CORPORATION (N : PRXL) Files An 8-K Submission of Matters ..
2017 PAREXEL INTERNATIONAL CORP : Submission of Matters to a Vote of Security Holders..
2017 PAREXEL INTERNATIONAL : Receives Shareholder Approval for Proposed Acquisition b..
More news
News from SeekingAlpha
2017 Microsoft and Parexel announce life science tech cloud initiative
2017 IWM : Small Caps Caution Is The Word
2017 GAINING ON S&P INDEX CHANGES : Six, stl, kem
2017 Stocks to Watch Next Week
2017 PAREXEL beats by $0.09, beats on revenue